Almanac Health, a Boston, MA–based unified clinical AI platform for clinical decision support, has raised $10 million in Seed funding. 

Investors 

The round was led by F-Prime, with participation from General Catalyst and Lightspeed Venture Partners. 

F-Prime is a global venture capital firm that invests in healthcare and technology companies. With decades of investing experience, it operates across stages from early venture to growth, while maintaining a strong emphasis on deep science, including biotechnology, therapeutics, and data-driven healthcare, alongside enterprise software and fintech. The firm manages $4.8 billion in assets under management (AUM). 

Almanac Health Use of Funds 

The company will use the funding to expand its team across clinical medicine, AI research, and health systems infrastructure, while advancing R&D focused on privacy, reliability, and rigorous clinical validation. 

About Almanac Health 

Founded by Cyril Zakka, Almanac Health is a clinical AI platform that delivers specialist-grade knowledge to clinicians at the point of care. It provides evidence-based clinical decision support across medical specialties, free from pharmaceutical advertising, and governed by institutional controls. Almanac Health integrates with existing EHR systems and is clinically validated through peer-reviewed research. 

Funding Details 

Company: Almanac Health, Inc. 

Raised: $10.0M 

Round: Seed 

Funding Date: April 2026 

Lead Investor: F-Prime 

Additional Investors: General Catalyst, Lightspeed Venture Partners 

Company Website: https://almanac.chat/  

Software Category: Healthcare AI / Clinical Decision Support 

Source: https://www.businesswire.com/news/home/20260422202186/en/